Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion

[1]  R. Morgan,et al.  Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition , 2010, The Journal of Immunology.

[2]  P. Muranski,et al.  Type 17 CD8+ T cells display enhanced antitumor immunity. , 2009, Blood.

[3]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[4]  R. Strong,et al.  Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain , 2009, The Journal of experimental medicine.

[5]  J. Wargo,et al.  Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression , 2009, Cancer Immunology, Immunotherapy.

[6]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Steinberg,et al.  Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines , 2008, Clinical Cancer Research.

[8]  B. Alarcón,et al.  Targeting the Wilms Tumor Antigen 1 by TCR Gene Transfer: TCR Variants Improve Tetramer Binding but Not the Function of Gene Modified Human T Cells1 , 2007, The Journal of Immunology.

[9]  S. Rosenberg,et al.  Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. , 2007, Cancer research.

[10]  Ralf-Holger Voss,et al.  Facilitating matched pairing and expression of TCR chains introduced into human T cells. , 2007, Blood.

[11]  B. Engels,et al.  Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy. , 2007, Molecular aspects of medicine.

[12]  S. Rosenberg,et al.  Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1 , 2006, The Journal of Immunology.

[13]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[14]  Yangbing Zhao,et al.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. , 2006, Cancer research.

[15]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[16]  J. Boulter,et al.  Stable, soluble, high‐affinity, engineered T cell receptors: novel antibody‐like proteins for specific targeting of peptide antigens , 2005, Clinical and experimental immunology.

[17]  S. Rosenberg,et al.  Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR , 2005, The Journal of Immunology.

[18]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[19]  S. Rosenberg,et al.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.

[20]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Richard A. Morgan,et al.  Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines , 2005, The Journal of Immunology.

[22]  S. Alexander,et al.  Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. , 2004, Blood.

[23]  Meir Glick,et al.  Stable, soluble T-cell receptor molecules for crystallization and therapeutics. , 2003, Protein engineering.

[24]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[25]  K. Cornetta,et al.  Clinical retroviral vector production: step filtration using clinically approved filters improves titers , 2000, Gene Therapy.

[26]  K. Cornetta,et al.  Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience. , 2000, Human gene therapy.

[27]  S. Rosenberg,et al.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.

[28]  J C Briggs,et al.  Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.

[29]  S. Riddell,et al.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. , 1990, Journal of immunological methods.

[30]  S. Rosenberg,et al.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.

[31]  M. Sanders,et al.  Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets. , 1988, Immunology today.

[32]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .